Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pressure ulcers management: an economic evaluation.
Foglia E, Restelli U, Napoletano AM, Coclite D, Porazzi E, Bonfanti M, Croce D. Foglia E, et al. Among authors: bonfanti m. J Prev Med Hyg. 2012 Mar;53(1):30-6. J Prev Med Hyg. 2012. PMID: 22803317
Health technology assessment in the HIV setting: the case of monotherapy.
Restelli U, Croce D, Porazzi E, Scolari F, Bonfanti M, Galli M, Gianotti N, Rizzardini G, Garagiola E, Vanzago A, Foglia E. Restelli U, et al. Among authors: bonfanti m. New Microbiol. 2014 Jul;37(3):247-61. Epub 2014 Jul 1. New Microbiol. 2014. PMID: 25180841 Free article.
TECHNOLOGY ASSESSMENT IN HOSPITALS: LESSONS LEARNED FROM AN EMPIRICAL EXPERIMENT.
Foglia E, Lettieri E, Ferrario L, Porazzi E, Garagiola E, Pagani R, Bonfanti M, Lazzarotti V, Manzini R, Masella C, Croce D. Foglia E, et al. Among authors: bonfanti m. Int J Technol Assess Health Care. 2017 Jan;33(2):288-296. doi: 10.1017/S0266462317000356. Epub 2017 Jun 5. Int J Technol Assess Health Care. 2017. PMID: 28578752
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
Restelli U, Alberti A, Lazzarin A, Bonfanti M, Nappi C, Croce D. Restelli U, et al. Among authors: bonfanti m. Eur J Health Econ. 2018 Jan;19(1):37-44. doi: 10.1007/s10198-016-0865-3. Epub 2016 Dec 22. Eur J Health Econ. 2018. PMID: 28008546
Organisational and financial consequences of the early discharge of patients treated for acute bacterial skin and skin structure infection and osteomyelitis in infectious disease departments in Greece, Italy and Spain: a scenario analysis.
Restelli U, Bonfanti M, Croce D, Grau S, Metallidis S, Moreno Guillén S, Pacelli V, Rizzardini G, Soro M, Vozikis A, Gray A. Restelli U, et al. Among authors: bonfanti m. BMJ Open. 2019 Sep 12;9(9):e031356. doi: 10.1136/bmjopen-2019-031356. BMJ Open. 2019. PMID: 31515433 Free PMC article.
Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients.
Restelli U, Rizzardini G, Antinori A, Lazzarin A, Bonfanti M, Bonfanti P, Croce D. Restelli U, et al. Among authors: bonfanti m, bonfanti p. Ther Clin Risk Manag. 2017 Jun 29;13:787-797. doi: 10.2147/TCRM.S135972. eCollection 2017. Ther Clin Risk Manag. 2017. PMID: 28721059 Free PMC article.
131 results